Patent directory · USPTO A61K / A61P
Patents matching “REGENERON PHARMACEUTICALS, INC.”
837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 12070506
Steroids and antibody-conjugates thereof
granted -
US 12066246
Target residual moisture content for lyophilized drug product
granted -
US 12068729
Anti-factor XII/XIIa antibodies and uses thereof
granted -
US 12065506
Anti-TMPRSS2 antibodies and antigen-binding fragments
granted -
US 12060419
CD79A chimeric antigen receptors
granted -
US 12060428
Anti-IL36R antibodies
granted -
US 12054557
Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer
granted -
US 12054532
Anti-VEGF protein compositions and methods for producing the same
granted -
US 12053534
Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
granted -
US 12054533
Anti-VEGF protein compositions and methods for producing the same
granted -
US 12049670
Proprotein convertase subtilisin/kexin type 1 (PCSK1) variants and uses thereof
granted -
US 12049489
Anti-VEGF protein compositions and methods for producing the same
granted -
US 12042538
Methods of reducing particle formation and compositions formed thereby
granted -
US 12036256
Adoptive cellular therapy
granted -
US 12037401
Anti-TrkB monoclonal antibodies and methods of use
granted -
US 12037411
Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof
granted -
US 12037388
Anti-IL-33 antibodies and uses thereof
granted -
US 12036280
High concentration protein formulation
granted -
US 12036288
Methods of using humanized FCγR mice to assay Fc regions
granted -
US 12029788
Methods for increasing lean body mass with an exercise regimen and a GDF8 inhibitor that is an anti-GDF8 antibody
granted -
US 12030935
Anti-PDGF-B antibodies and pharmaceutical composition thereof
granted -
US 12024556
Anti-Staphylococcus antibodies and uses thereof
granted -
US 12024570
Anti-CTLA-4 antibodies and uses thereof
granted -
US 12018259
Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors
granted